drugset / Trial / NCT06410703
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic Advanced Solid Tumors who have exhausted options for standard of care therapy.
Timeline
- Start
- 2024-06-27
- Primary completion
- 2025-05-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAN1012 | Unknown | 0.01 mg | Other |
| Subject | CAN1012 | Unknown | 0.017 mg | Other |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |